News | Hypertension | July 15, 2020

Omron and Mount Sinai Health Collaborate to Monitor High-risk Patient Blood Pressure at Home

Technology ensures close connection between patient and physician for remote hypertension monitoring, including COVID-19 patients

VitalSight is a HIPAA-compliant, Medicare-reimbursable home blood pressure monitoring solution that generally comes at no cost to the patient, depending on their coverage. The kit typically includes a digital blood pressure monitor with cuff, weight scale and digital medication tracker, as well as a data hub.

July 15, 2020 – Omron Healthcare Inc. and Mount Sinai Health System, New York City’s largest academic medical system, have teamed to offer patients the new VitalSight home blood pressure monitoring solution. Mount Sinai recently rolled out the VitalSight program to support the needs of their patients with hypertension.

The effort to provide VitalSight to patients is led by Rob Fields, M.D., SVP and chief medical officer for population health at Mount Sinai, and a team of clinical pharmacists, who are responsible for the day-to-day management of the program and coordination with physicians to ensure that patients receive individualized care.  

“The ability to monitor patients at home during the pandemic – and on an ongoing basis – is critical. Our collaboration with Omron Healthcare helps make patients active participants in their own healthcare and extends the reach of clinicians, who receive a continuous stream of their patients’ real-time health data so that they can proactively intervene as necessary,” Fields  said. “Additionally, we are focusing first on our most vulnerable patients, who bear the consequences of disparities in care – in part, due to lack of technology access. This program requires no technology and comes at no cost for the device, with little-to-no cost for service.”

“We’re excited to collaborate with such a prestigious healthcare institution as Mount Sinai, who played an instrumental role in shaping the value of VitalSight from early in its development. Now, they are leading the way for patients to use VitalSight from the privacy of their home, while staying closely connected to their physician,” explained Omron Healthcare President and CEO Ranndy Kellogg. 

VitalSight is the newest addition to the line of Omron Healthcare home blood pressure monitors, which are among the top doctor and pharmacist recommended systems.[1,2] The VitalSight kit complements Mount Sinai’s commitment to remotely monitor patients as part of its recent telehealth initiative, especially as providers care for COVID-19 patients who are recovering at home. 

VitalSight is a HIPAA-compliant, Medicare-reimbursable home blood pressure monitoring solution that generally comes at no cost to the patient, depending on their coverage. The kit typically includes a digital blood pressure monitor with cuff, weight scale and digital medication tracker, as well as a data hub. Exact devices may vary based on what the physician deems appropriate for each patient’s hypertension monitoring needs. VitalSight directly links to a physician’s electronic medical record (EMR), and is compatible with leading systems. Patients measure their blood pressure, weigh themselves and continue to take their medication as ordered by their physician. Securely encrypted data is automatically sent to the doctor’s EMR in real time, where it’s stored for reference unless a health concern is detected, in which case the physician’s office is alerted.

For more information: www.omronhealthcare.com

References:
1. Frost & Sullivan Survey, Blood pressure clinician perception tracker surveys. 17 July 2019.

2. U.S. News Staff 2019, U.S. News & World Report. https://health.usnews.com/health-products/top-rec-blood-pressure-monitors-14, accessed 8 August 2019.
 

Related Content

#breakingnews The U.S. Food and Drug Administration (FDA) just granted full approval to the Pfizer/BioNTech Covid-19 vaccine for people age 16 and older. It is the first vaccine to be fully approved by the FDA, and experts say it is expected to open the door for further vaccine mandates.

Getty Images

News | Coronavirus (COVID-19) | August 23, 2021
August 23, 2021 — The U.S.
The American Heart Association announced its support this week for the CDC and FDA recommendation that immuno-compromised patients should receive a third dose of the Pfizer or Moderna COVID vaccines. Getty Images #AHA #coronavirus #COVID19

The American Heart Association announced its support this week for the CDC and FDA recommendation that immuno-compormised patients should receive a third dose of the Pfizer or Moderna COVID vaccines. Getty Images

News | Coronavirus (COVID-19) | August 18, 2021 | By Dave Fornell, Editor
August 18, 2021 — The U.S.
In an effort to contain COVID-19 and the new rapid spread of the delta virus across the U.S., a coalition of 10 cardiovascular societies issued a statement of support for healthcare systems requiring COVID-19 vaccines for its employees. ACC, HRS, ASNC, SCMR, SCCT, ASE, HFSA, STS, SCAI.

In an effort to contain COVID-19 and the new rapid spread of the delta virus across the U.S., a coalition of 10 cardiovascular societies issued a statement of support for healthcare systems requiring COVID-19 vaccines for its employees. 

Feature | Coronavirus (COVID-19) | July 30, 2021 | By Dave Fornell, Editor
July 30, 2021 — A coalition of 10 U.S.-based cardiovascular societies have issued a statement today in support of all
AHA president says COVID has a direct impact on the heart and preventive measures for heart disease largely went out the window during the pandemic

Getty Images

News | Coronavirus (COVID-19) | July 26, 2021
July 26, 2021 — Heart disease and stroke continue to kill more people in the U.S.
A new study with data from more than 10,000 COVID patients confirmed that patients taking statin medications had a 41 percent lower risk of in-hospital death from COVID-19.

A new study with data from more than 10,000 COVID patients confirmed that patients taking statin medications had a 41 percent lower risk of in-hospital death from COVID-19. Researchers believe statins, which attach to the ACE2 receptors, may block the virus from attaching to these same receptors. 

News | Coronavirus (COVID-19) | July 21, 2021
July 21, 2021 — In a new study from University of California San Diego School of Medicine, researchers have confirmed
New trial results from the international RAPID Trial show that administering a full dose of a standard blood thinner early to moderately ill hospitalized patients with COVID-19 could halt the thrombo-inflammation process and reduce the risk of severe disease and death. How to anticoagulate COVID patients. How to prevent thrombus in COVID patients.

New trial results from the international RAPID Trial show that administering a full dose of a standard blood thinner early to moderately ill hospitalized patients with COVID-19 could halt the thrombo-inflammation process and reduce the risk of severe disease and death. Getty Images
 

Feature | Coronavirus (COVID-19) | July 15, 2021
July 15, 2021 — COVID-19 is m
Diluting of a blood sample for real-time deformability cytometry testing. Researchers at the Max-Planck-Zentrum für Physik und Medizin in Erlangen. Germany, were able to show for the first time COVID-19 significantly changes the size and stiffness of red and white blood cells, sometimes over months. From the study How a COVID-19 Infection Changes Blood Cells in the Long Run. Reasons for long COVID.

Diluting of a blood sample for real-time deformability cytometry testing. Researchers at the Max-Planck-Zentrum für Physik und Medizin in Erlangen. Germany, were able to show for the first time COVID-19 significantly changes the size and stiffness of red and white blood cells, sometimes over months.

News | Coronavirus (COVID-19) | July 15, 2021
July 15, 2021 — Using real-time deformability cytometry, researchers at the...
Researchers analyzing surveillance data on 518 children and adolescents with MIS-C who were admitted to U.S. hospitals in 2020 fopiund those treated with intravenous immune globulin (IVIG) plus glucocorticoids had a lower risk of new or persistent cardiovascular dysfunction than IVIG alone. Left photo Getty Images, right photo Nemours Children’s Health System.

Researchers analyzing surveillance data on 518 children and adolescents with MIS-C who were admitted to U.S. hospitals in 2020 fopiund those treated with intravenous immune globulin (IVIG) plus glucocorticoids had a lower risk of new or persistent cardiovascular dysfunction than IVIG alone. Left photo Getty Images, right photo Nemours Children’s Health System.

News | Coronavirus (COVID-19) | June 28, 2021
June 28, 2021 - A recent analysis found that children and adolescents with multisystem inflammatory syndrome in child
The U.S. Food and Drug Administration (FDA) announced June 25 it has added a warning on the Moderna and Pfizer COVID-19 messenger RNA (mRNA) vaccine fact sheets to explain they may cause myocarditis in rare cases as a side effect. The agency said the side effect is very rare and patients generally recover quickly, but it can disportionally affect younger patients in their teens and early 20s. Getty Images

Getty Images

News | Coronavirus (COVID-19) | June 28, 2021 | Dave Fornell, Editor
June 28, 2021 — The U.S.
A small number of patients develop myocarditis after receiving the messenger RNA (mRNA) COVID-19 vaccines from Pfizer and Moderna. This recently raised concerns after numbers for this adverse reaction jumped in April and May, prompting review this week by the Centers for Disease Control and Prevention (CDC) Advisory Committee on the Immunization Practices (ACIP).

A small number of patients develop myocarditis after receiving the messenger RNA (mRNA) COVID-19 vaccines from Pfizer and Moderna. This recently raised concerns after numbers for this adverse reaction jumped in April and May, prompting review this week by the Centers for Disease Control and Prevention (CDC) Advisory Committee on the Immunization Practices (ACIP). Getty Images

Feature | Coronavirus (COVID-19) | June 24, 2021 | By Dave Fornell, Editor
A small number of patients develop inflammation leading to myocarditis after receiving the messenger RNA (mRNA)...